Decision tool to help you choose radioactive iodine after intermediate-risk thyroid cancer
Official title: Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial
Funded at Georgetown University · NIH-11294188 · Data updated 2026-11-12
A patient-friendly decision aid will help people with intermediate-risk thyroid cancer weigh the benefits and risks of adding radioactive iodine after surgery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 5, 2022 |
| Project end | January 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $735,331 |
| NIH project number | 5UH3DE031248-04 |
| Project ID | NIH-11294188 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with intermediate-risk differentiated thyroid cancer who are deciding whether to receive radioactive iodine after surgery.
✕Less likely to help
Patients for whom RAI is already clearly recommended (high-risk) or clearly not recommended (low-risk), or those not currently facing the RAI decision, are unlikely to benefit from this tool.
What this research studies
If you have intermediate-risk differentiated thyroid cancer and are deciding between surgery alone or surgery plus radioactive iodine (RAI), this project offers a clear decision aid to explain the possible benefits, side effects, and uncertainties. The team will build the tool using existing evidence and patient input, then offer it to patients who are facing this treatment choice. Researchers will track how the tool affects what patients choose, how confident they feel about their decision, and short-term quality-of-life outcomes.
Why it matters
Potential benefit: If successful, the decision aid could reduce uncertainty, improve informed decision-making, and help avoid unnecessary RAI and its side effects.
How similar studies have gone: Decision aids have improved knowledge and reduced decisional conflict in other cancer treatment choices, but applying one specifically to RAI decisions in intermediate-risk thyroid cancer is relatively new.
Where this research is happening
-
Georgetown University
Washington, United States Active
Researchers
- Principal investigator: Jonklaas, Jacqueline — Georgetown University
- Study coordinator: Jonklaas, Jacqueline
Related research
Other NIH-funded projects on the same topics.
-
WTC Dust and Thyroid Cancer Progression in Human Organoids
This grant tests how World Trade Center dust might influence thyroid cancer progression using human thyroid organoids to model real-life exposure.
-
Integrating molecular signals to guide thyroid cancer care
A doctor-scientist team at Brigham and Women’s Hospital is studying how tumor biology and the immune environment can guide personalized monitoring and treatment for differentiated thyroid cancer.
-
Metabolic Imaging to Track Treatment Response in Aggressive Thyroid Cancer
This grant explores a new way to watch how aggressive thyroid cancers respond to treatment using a special MRI technique that tracks tumor metabolism.
-
Adoptive T-cell Therapy for Anaplastic Thyroid Cancer
A patient-focused program explores using patient immune cells engineered to target and fight anaplastic thyroid cancer, especially for those whose cancer has stopped responding to standard treatments.
-
Overcoming Resistance to BRAF Inhibitors in Aggressive Thyroid Cancers
A patient-focused research effort to find new ways to treat difficult thyroid cancers that no longer respond to current BRAF inhibitors.
-
Improving Treatment of Anaplastic Thyroid Cancer with New Therapies and Early Response Checks
This NIH grant aims to advance treatment for a rare, aggressive thyroid cancer by testing new approaches and measuring how tumors respond early in treatment to tailor care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.